The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented is solely approved for use in the US by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The compound is still being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.
European Society of Cardiology Congress 2021 Hot Line: FIGARO-DKD PresentationAugust 27-30, 2021
Effect of finerenone on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes: results of the FIGARO-DKD trial
Thank you for your interest in the results of the FIGARO-DKD trial. The peer-reviewed publication of FIGARO-DKD has been published in the New England Medical Journal and is available here.
Please see below to download the presented slides in PowerPoint, available in English, Spanish, German, French, Mandarin, Japanese and Portuguese.
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Finerenone
Saturday 28 August, 2021 | 17:25 - 18:10 CEST
Effect of finerenone on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes: results of the FIGARO-DKD trial
Download the presented slides in English here.
Session: HotlineSpeaker: Bertram Pitt
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Saturday 28 August, 2021 | 17:25 - 18:10 CEST
Effect of finerenone on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes: results of the FIGARO-DKD trial
For your convenience, you can download the presented slides in Spanish here
Session: HotlineSpeaker: Bertram Pitt
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Saturday 28 August, 2021 | 17:25 - 18:10 CEST
Effect of finerenone on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes: results of the FIGARO-DKD trial
For your convenience, you can download the presented slides in German here
Session: HotlineSpeaker: Bertram Pitt
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Saturday 28 August, 2021 | 17:25 - 18:10 CEST
Effect of finerenone on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes: results of the FIGARO-DKD trial
For your convenience, you can download the presented slides in French here
Session: HotlineSpeaker: Bertram Pitt
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Saturday 28 August, 2021 | 17:25 - 18:10 CEST
Effect of finerenone on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes: results of the FIGARO-DKD trial
For your convenience, you can download the presented slides in Portuguese here
Session: HotlineSpeaker: Bertram Pitt
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Saturday 28 August, 2021 | 17:25 - 18:10 CEST
Effect of finerenone on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes: results of the FIGARO-DKD trial
For your convenience, you can download the presented slides in Mandarin here
Session: HotlineSpeaker: Bertram Pitt
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Saturday 28 August, 2021 | 17:25 - 18:10 CEST
Effect of finerenone on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes: results of the FIGARO-DKD trial
For your convenience, you can download the presented slides in Japanese here
Session: HotlineSpeaker: Bertram Pitt
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
More Information
For more information regarding Finerenone visit us by clicking the link below
The compound presented is approved for use by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D) but is investigational or being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.
Date accessed: 1 September, 2021
MA-M_FIN-ALL-0422-1